Abafungin: Difference between revisions
Appearance
Content deleted Content added
No edit summary |
Rescuing 1 sources and tagging 0 as dead. #IABot (v1.2.4) |
||
Line 55: | Line 55: | ||
'''Abafungin''' ([[International Nonproprietary Name|INN]]) is a broad-spectrum [[antifungal agent]] with a novel mechanism of action for the treatment of [[dermatomycoses]]. |
'''Abafungin''' ([[International Nonproprietary Name|INN]]) is a broad-spectrum [[antifungal agent]] with a novel mechanism of action for the treatment of [[dermatomycoses]]. |
||
'''Abasol''' is a topical cream formulation of abafungin by [[York Pharma]].<ref>[http://www.yorkpharma.com/media/YRK-Update_Abasol_061002-FN.pdf York Pharma: Regulatory Update – Abasol]</ref> |
'''Abasol''' is a topical cream formulation of abafungin by [[York Pharma]].<ref>[http://www.yorkpharma.com/media/YRK-Update_Abasol_061002-FN.pdf York Pharma: Regulatory Update – Abasol] {{wayback|url=http://www.yorkpharma.com/media/YRK-Update_Abasol_061002-FN.pdf |date=20070927102715 }}</ref> |
||
==Mechanism of action== |
==Mechanism of action== |
Revision as of 06:34, 2 October 2016
Clinical data | |
---|---|
Trade names | Abasol |
Routes of administration | Topical (cream) |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.125.129 |
Chemical and physical data | |
Formula | C21H22N4OS |
Molar mass | 378.491 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Abafungin (INN) is a broad-spectrum antifungal agent with a novel mechanism of action for the treatment of dermatomycoses.
Abasol is a topical cream formulation of abafungin by York Pharma.[1]
Mechanism of action
Unlike imidazole- and triazole-class antifungals, abafungin directly impairs the fungal cell membrane.[2]
In addition, abafungin inhibits the enzyme sterol 24-C-methyltransferase, modifying the composition of the fungal membrane.[3]
Abafungin has antibiotic activity against gram-positive bacteria as well as sporicidal activity.[4]
References
- ^ York Pharma: Regulatory Update – Abasol Archived (Date missing) at yorkpharma.com (Error: unknown archive URL)
- ^ Borelli C1, Schaller M, Niewerth M, Nocker K, Baasner B, Berg D, Tiemann R, Tietjen K, Fugmann B, Lang-Fugmann S, Korting HC. "Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi". Chemotherapy. 2008;54(4):245-59
- ^ Borelli C1, Schaller M, Niewerth M, Nocker K, Baasner B, Berg D, Tiemann R, Tietjen K, Fugmann B, Lang-Fugmann S, Korting HC. "Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi". Chemotherapy. 2008;54(4):245-59
- ^ Ginter-Hanselmayer, Gabriele (March 2009), Arbeitsunterlagen zur 42. wissenschaftlichen Fortbildungsveranstaltung für Apothekerinnen und Apotheker: Infektionskrankheiten, Österreichische Apothekerkammer, p. 103